# Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

> **NCT01462266** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 660 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Comparator: Placebo
- **BIOLOGICAL:** Insulin Glargine
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01462266
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-13
- **Primary completion:** 2013-06-06
- **Final completion:** 2013-06-07
- **Target enrollment:** 660 (ACTUAL)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01462266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01462266, "Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01462266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*